These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 17338662

  • 1. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
    Kapur NK.
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
    [Abstract] [Full Text] [Related]

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May 16; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 9. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH, Carter MD, Lavie CJ, Bell DS.
    Postgrad Med; 2009 May 16; 121(3):113-8. PubMed ID: 19491548
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED, Blumenthal RS.
    J Am Coll Cardiol; 2009 Mar 17; 53(11):931-5. PubMed ID: 19281922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ, Uno K, Kataoka Y.
    Expert Rev Cardiovasc Ther; 2011 Nov 17; 9(11):1383-90. PubMed ID: 22059787
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Review of efficacy of rosuvastatin 5 mg.
    Teramoto T, Watkins C.
    Int J Clin Pract; 2005 Jan 17; 59(1):92-101. PubMed ID: 15707472
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH.
    Clin Ther; 2007 Nov 17; 29(11):2385-94. PubMed ID: 18158079
    [Abstract] [Full Text] [Related]

  • 17. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA.
    Future Cardiol; 2009 May 17; 5(3):231-6. PubMed ID: 19656039
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA, Izar MC.
    Expert Rev Cardiovasc Ther; 2009 Sep 17; 7(9):1041-56. PubMed ID: 19764857
    [Abstract] [Full Text] [Related]

  • 20. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Barrios V, Escobar C.
    Expert Rev Cardiovasc Ther; 2009 Nov 17; 7(11):1317-27. PubMed ID: 19900015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.